Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00690924 · ClinicalTrials.gov registry record · NA
Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer
A NA study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT00690924 is a NA study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 16 participants.
The verdict
NCT00690924, a NA study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
RATIONALE: Calcitriol may prevent lung cancer in patients with metaplasia or dysplasia of the lungs. PURPOSE: This clinical trial is studying the side effects and best dose of calcitriol in preventing lung cancer in current smokers and former smokers at high risk of lung cancer.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG calcitriol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-07-17 |
| Est. Completion | 2018-03-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00690924
The ClinicalTrials.gov registry entry for NCT00690924 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00690924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00690924 about?
NCT00690924 is a clinical study titled "Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer". RATIONALE: Calcitriol may prevent lung cancer in patients with metaplasia or dysplasia of the lungs. PURPOSE: This clinical trial is studying the side effects and best dose of calcitriol in preventing lung cancer in current smokers and former smokers at high risk of lung cancer.
What is the current status of trial NCT00690924?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2008-07-17. Estimated completion is 2018-03-07.
What interventions are being tested in trial NCT00690924?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), calcitriol (DRUG).
Who is sponsoring clinical trial NCT00690924?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.